Article Text
Abstract
Introduction E-cigarette users typically initiate vaping with flavoured e-liquids. People who vape flavours tend to underestimate the harm of vaping. We examined the inter-relationship between flavour preference, vaping for cessation purposes, e-cigarette dependence, e-cigarette harm perception and purchase/use intention, given a hypothetical flavour ban. We hypothesised that non-tobacco flavour preference and vaping for cessation would be negatively associated with harm perception of e-cigarettes and intention to continue vaping if a flavour ban occurred and that these effects would be mediated by e-cigarette dependence.
Methods From July 2019 to March 2020, we conducted intercept interviews with 276 customers at 44 vape shops in California. The predictor variables were flavour preference and vaping for cessation. The outcome variables were harm perception of e-cigarettes and intention to purchase/use, given a hypothetical flavour ban. Multilevel structural equation modelling tested whether e-cigarette dependence mediates the effects of flavour preference on hypothetical continued vaping and purchase.
Results Those who preferred flavours showed significantly lower intention to purchase e-liquids (β=−0.28, p<0.001) and to continue vaping (β=−0.17, p=0.001), given a hypothetical flavour ban. Those who vaped for smoking cessation indicated greater intention to purchase e-liquid (β=0.10, p=0.016) and to continue vaping (β=0.17, p=0.001), given a hypothetical flavour ban. E-cigarette dependence significantly mediated these effects (ps<0.04).
Discussion Flavour preference was negatively related to intention to continue to vape within a hypothetical flavour ban. Our results also highlight the importance of e-cigarette dependence and use of e-cigarettes as smoking cessation methods. Implications for future flavour bans are discussed.
- electronic nicotine delivery devices
- public policy
- harm reduction
Statistics from Altmetric.com
Footnotes
Contributors All authors have contributed to the manuscript.
Funding Research reported in this publication was supported by a California Tobacco-Related Disease Research Program Award (TRDRP Grant #26IR-0016) and a National Cancer Institute and FDA Center for Tobacco Products (CTP) Award (NCI/FDA Grant #U54CA180905). The content is solely the responsibility of the authors and does not necessarily represent the official views of TRDRP, the NIH or the Food and Drug Administration.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.